Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2024-11-06 Earnings Release
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
Earnings Release Classification · 95% confidence The document is explicitly titled '# **Press Release**' and announces a regulatory approval (Dupixent approved in the EU for young children with eosinophilic esophagitis) along with clinical trial data and quotes from management. This format is characteristic of an Earnings Release (ER) or a general announcement. Since it is a press release announcing a significant event (regulatory approval and clinical data summary) rather than a formal, comprehensive financial report (like 10-K or IR), the most appropriate classification among the options provided is 'Earnings Release' (ER), as these often accompany or precede formal financial filings to disseminate key news. It is not a Call Transcript (CT), Audit Report (AR), or a formal regulatory filing like 10-K. Given the content focuses on product news and clinical milestones, ER is the best fit for a major corporate announcement of this nature. Q4 2024
2024-11-06 English
6-K
Regulatory Filings
2024-10-31 English
6-K
Regulatory Filings
2024-10-25 English
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
Earnings Release Classification · 100% confidence The document is titled "Press Release" and contains key financial highlights for Q3 2024, including sales figures, EPS, pipeline progress, and updated 2024 guidance. The structure, content (quarterly results, segment breakdown, CEO commentary), and explicit mention of Q3 performance strongly indicate this is an Earnings Release (ER). It is not a full Annual Report (10-K), nor is it a short announcement merely stating a report is attached (RPA/RNS). It provides the initial, summarized financial results for the period. Q3 2024
2024-10-25 English
Communiqué de presse : T3 2024 : Croissance des ventes de 15,7% soutenue par une séquence des ventes de vaccins plus favorable qu’anticipée; Sanofi relève ses perspectives de BNPA des activités 2024 s
Earnings Release Classification · 100% confidence The document is a press release ("Communiqué de presse") detailing the financial results for the third quarter (T3 2024) and the first nine months of 2024. It includes key financial metrics (sales growth, EPS, cash flow), operational highlights, pipeline updates, and management commentary. This structure, focusing on period-specific financial performance announcements, strongly aligns with the definition of an Earnings Release (ER). While it contains comprehensive data, its format as a press release announcing the results, rather than a formal regulatory filing like a 10-K or IR, points towards ER. It is not a short announcement linking to a report (RPA/RNS), as it contains the core results summary itself. Q3 2024
2024-10-25 French
Communiqué de presse : Dupixent : Présentation de nouvelles données positives de phase III dans le traitement de l’urticaire chronique spontanée au Congrès de l’ACAAI
Regulatory Filings Classification · 96% confidence The document is titled "Communiqué de presse" (Press Release) and details positive Phase III clinical trial data for the drug Dupixent in treating chronic spontaneous urticaria (CSU). It announces that these data will be presented at the ACAAI scientific congress and will support a regulatory submission renewal in the US by year-end. This format—a formal announcement of scientific/clinical results, often preceding or accompanying a major regulatory filing or presentation, and structured as a news release—is characteristic of an Earnings Release (ER) or a general announcement. Since it is not a full financial report (10-K/IR), a transcript (CT), or a specific regulatory form, and it is announcing key results rather than just the publication of a report (RPA), the most fitting category for a press release announcing significant clinical/business updates is the Earnings Release (ER) category, which often encompasses major operational or clinical milestones announced via press release. Given the context of clinical trial results and regulatory updates, it functions as a major corporate announcement.
2024-10-24 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.